Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 80.33% | Jefferies | $4 → $11 | Upgrades | Hold → Buy |
| 10/26/2023 | 31.15% | Morgan Stanley | $4 → $8 | Upgrades | Underweight → Equal-Weight |
| 08/15/2023 | 80.33% | SVB Securities | $6 → $11 | Maintains | Outperform |
| 08/15/2023 | 63.93% | Guggenheim | $9 → $10 | Maintains | Buy |
| 08/15/2023 | -18.03% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
| 07/25/2023 | 145.9% | BMO Capital | $11 → $15 | Maintains | Outperform |
| 06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/12/2023 | 47.54% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
| 05/15/2023 | -26.23% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
| 03/17/2023 | -1.64% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 01/24/2023 | -34.43% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
| 08/12/2022 | -18.03% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
| 08/11/2022 | 80.33% | BMO Capital | $19 → $11 | Maintains | Outperform |
| 08/11/2022 | -34.43% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 07/15/2022 | 63.93% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
| 06/17/2022 | 211.48% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 145.9% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
| 05/24/2022 | 31.15% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
| 04/05/2022 | 211.48% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 06/23/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 588.52% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 06/22/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 473.77% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 80.33% | 傑富瑞集團 | 4 美元 → 11 美元 | 升級 | 持有 → 買入 |
| 2023 年 10 月 26 日 | 31.15% | 摩根士丹利 | 4 美元 → 8 美元 | 升級 | 體重不足 → 重量相等 |
| 08/15/2023 | 80.33% | SVB 證券 | 6 美元 → 11 美元 | 維護 | 跑贏大盤 |
| 08/15/2023 | 63.93% | 古根海姆 | 9 美元 → 10 美元 | 維護 | 買 |
| 08/15/2023 | -18.03% | 高盛 | 4.5 美元 → 5 美元 | 維護 | 中立 |
| 07/25/2023 | 145.9% | BMO Capital | 11 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 06/21/2023 | — | Evercore ISI 集團 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 06/12/2023 | 47.54% | 古根海姆 | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/15/2023 | -26.23% | 高盛 | 4 美元 → 4.5 美元 | 維護 | 中立 |
| 03/17/2023 | -1.64% | SVB Leerink | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 01/24/2023 | -34.43% | 摩根士丹利 | 5 美元 → 4 美元 | 維護 | 體重不足 |
| 2022 年 12 月 8 日 | -18.03% | 摩根士丹利 | 10 美元 → 5 美元 | 降級 | 超重 → 體重不足 |
| 08/11/2022 | 80.33% | BMO Capital | 19 美元 → 11 美元 | 維護 | 跑贏大盤 |
| 08/11/2022 | -34.43% | 高盛 | 5 美元 → 4 美元 | 維護 | 中立 |
| 07/15/2022 | 63.93% | 摩根士丹利 | 15 美元 → 10 美元 | 維護 | 超重 |
| 2022 年 6 月 17 日 | 211.48% | BMO Capital | → 19 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2022 年 5 月 24 日 | 145.9% | 摩根士丹利 | 19 美元 → 15 美元 | 維護 | 超重 |
| 2022 年 5 月 24 日 | 31.15% | 高盛 | 12 美元 → 8 美元 | 維護 | 中立 |
| 2022 年 5 月 4 日 | 211.48% | 摩根士丹利 | 20 美元 → 19 美元 | 維護 | 超重 |
| 06/23/2021 | 506.56% | 摩根士丹利 | → 37 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/22/2021 | 588.52% | 高盛 | → 42 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/22/2021 | 506.56% | 摩根士丹利 | → 37 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 06/22/2021 | 473.77% | 傑富瑞集團 | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals（CNTA）的目標價格是多少？
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Jefferies on November 15, 2023. The analyst firm set a price target for $11.00 expecting CNTA to rise to within 12 months (a possible 80.33% upside). 11 analyst firms have reported ratings in the last year.
傑富瑞集團於2023年11月15日公佈了Centessa Pharmicals（納斯達克股票代碼：CNTA）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計CNTA將在12個月內升至12個月內（可能上漲80.33％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals（CNTA）的最新分析師評級是多少？
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Jefferies, and Centessa Pharmaceuticals upgraded their buy rating.
傑富瑞集團提供了Centessa Pharmicals（納斯達克股票代碼：CNTA）的最新分析師評級，Centessa Pharmicals上調了買入評級。
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals（CNTA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Centessa Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Centessa Pharmicals的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
分析師對Centessa Pharmicals（CNTA）的評級正確嗎？
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a upgraded with a price target of $4.00 to $11.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.10, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Centessa Pharmicals（CNTA）評級已上調，目標股價爲4.00美元，至11.00美元。Centessa Pharmicals（CNTA）目前的交易價格爲6.10美元，在分析師的預測區間內。